



Palo Alto Health Sciences Chief Clinical Officer Dr. Robert Cuyler to Present Webinar on Tele-therapy for Mental Health

Danville, CA – (February 10, 2017) – Palo Alto Health Sciences (PAHS), developer of the *Freespira*[®] in-home treatment for panic and symptoms of panic, today announced that Chief Clinical Officer Dr. Robert Cuyler, PhD will conduct a webinar titled “Optimizing Your Clinical Practice for Tele-Therapy.” The event, which takes place February 23rd, is provided by the Anxiety and Depression Association of America (ADAA), a professional society serving mental health care treatment providers.

“Tele-therapy is an emerging modality that enables mental health professionals to provide treatment to patients who have difficulty consistently coming to the office for face-to-face therapy,” said Dr. Cuyler, who has extensively studied telemedicine for over a decade. PAHS CEO, Debra Reisenhel, added: “Dr. Cuyler is a recognized pioneer in the field of telemedicine and we are pleased that ADAA has invited him to present this webinar. We also believe that *Freespira*, because it is an in-home treatment, is particularly well-suited for tele-therapy.”

Mental health providers can learn more and register for Dr. Cuyler’s presentation at <https://www.adaa.org/resources-professionals/conference-education/professional-webinars#teletherapy>

About Palo Alto Health Sciences, Inc. and Freespira

Palo Alto Health Sciences, Inc. is a privately held Silicon Valley company at the forefront of revolutionizing behavioral healthcare with evidence-based, non-invasive, drug-free solutions. The Company’s first product, *Freespira*, is an FDA-cleared treatment for individuals suffering from panic attacks and other symptoms of panic. In the United States, over 6.7 million adults annually suffer from Panic Disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders. Patients with panic disorder often chronically hyperventilate, even when not experiencing a panic attack, and this abnormal breathing pattern has been shown to exacerbate attacks. *Freespira* works by training the patient to stabilize their respiration rate and reduce hyperventilation. Over the course of treatment, *Freespira* eliminates or reduces the symptoms of panic and panic attacks. *Freespira* is commercially available throughout the U.S. and therapists are successfully treating patients with outstanding results, even in the most severe cases. To learn more, visit <http://www.freespira.com> or contact info@pahealthsciences.com.

MEDIA CONTACT

Michele Kong

michele@pahealthsciences.com